Stress-Induced Bacterial Adaptation, Persistence, and Tolerance: Hidden Drivers of Treatment Failure and Recurrent Infections

Introduction

Management of bacterial infections depends on precise identification, the right antibiotic treatment, and optimized duration for therapy. However, there are cases of infections that keep causing tension or come back again after antibiotic use, even if the organism is sensitive, which is experienced frequently in hospital practice [1]. In the past, such instances were linked to antimicrobial resistance, so focus needs to be placed on resistance monitoring and research into new antibiotics. Resistance remains a main challenge in the global health system, but it cannot strictly provide an answer to the rising amount of failed treatments observed in many acute and chronic infections [2]. 

More attention is now going to stress-driven bacterial adaptation, which is an impactful but usually not very noticeable factor in why treatments fail. Bacteria both in patient bodies and in hospital settings face changing and tough conditions, including stress from immunity, low nutrition, exposure to antibiotics, and physical difficulties because of biofilm creation [3]. The result is that bacterial groups can make changes in nongenetic ways for improved survival, without depending on permanent genetic mutations. These stress reactions could cause specialized sets of bacteria that have less metabolic activity and more resistance to antibiotic drugs [4]. Within adaptive phenotypes, microbial persistence and tolerance to antibiotics receive more attention because their connection with repeated infection and chronic cases is strong [5]. Persister cells consist of a small population of bacteria that can survive at lethal antibiotic levels by entering a transient dormancy state [6]. Tolerant cells display a lower rate of being killed, yet do not have the regular resistance mechanisms normally used. Unlike resistance, these traits are not permanent, so they tend to go unnoticed in typical antimicrobial susceptibility tests, making decision-making for clinicians harder in practice [7].

Clinical consequences of persistence and tolerance are considerable. These phenotypes lead to infections lasting longer;e treatment must be extended in duration, raising the possibility of improved health care expenses [8]. Also, persistent bacteria can be a storehouse in the process for true antimicrobial resistance to eventually arise. Although these are important in context, these phenomena are still not well put into everyday diagnosis frameworks and in the application of treatment approaches [9]. This review targets offering an overview of stress-induced bacterial adaptations, with a specific focus on persistence and tolerance that work as undiscovered causes of treatment not working and infections coming back again. By looking at basic mechanisms, effects in the clinical context, and the diagnostic limits at present, the article tries to point out important gaps in the clinical microbiology area and describes future ideas for developing better ways to manage infections caused by bacteria that are hard to treat [10].

 

 

2. Bacterial Stress Responses in Clinical Environments

Bacteria that cause clinical infections rarely find themselves in stable or good environments. Mostly, they deal with dynamic and even unfriendly environments created by host defense mechanisms, antimicrobial therapies, and healthcare-related factors [11]. These kinds of stressors give strong selection pressure, causing bacteria to make adaptive reactions so that they can survive through infection or treatment. Seeing the types of these stresses is important to understand survival strategies in clinical situations that are not genetic; for example, persistence and tolerance can be evolved in such settings [12].

2.1 Host-Induced Stress

Inside the human body, invasive bacteria encounter many immune-causing stressors, which try to limit microbial growth and to clear the infection. Immune system features, like neutrophils and macrophages doing phagocytosis, put bacteria in contact with reactive oxygen species, antimicrobial proteins, and breaking enzymes [13]. This oxidative or nitrosative stress causes damage to bacterial proteins and membranes, so pathogens must activate stress response pathways for protection. Besides immune acts, bacteria need adaptation for nutritional immunity, which is a defense strategy from the host limiting entry of nutrients such as iron, zinc, and manganese [14]. Fewer nutrients available lead to bacteria feeling metabolic stress and not being able to grow well, favoring the creation of slow or sleep bacterial subgroups [15]. Also, local shifts in pH, oxygen levels, and osmolarity inside infected tiscreate make microenvironments that are harder for the survival of bacteria. Altogether, host-induced stress brings on phenotypic differences among bacteria, letting part of cell groups to be in a stress-resistant position [16].

2.2 Antibiotic-Induced Stress

Antibiotic exposure is one of the most important stress factors bacteria face during the clinical infection period. While antibiotics aim to remove pathogens, sub-lethal or shifting drug amounts often occur inside patients from variability in drug movement, poor tissue penetration, or failing to adhere to the treatment. These situations do not instantly destroy bacteria but induce stress responses that sometimes make survival stronger [17]. Antibiotics directed at major cell processes like wall building, DNA copying, or making proteins can switch on global stress systems. Responses can consist of DNA repair mechanisms, metabolic changes, and growth stop, which overall reduce the antibiotic’s working ability [18]. Significantly too is when antibiotic-caused stress leads to more persister cell creation or tolerant traits, but does not push for permanent genetic resistance. In a clinical view, such survival through stress means longer infections, higher chances of the disease coming back after treatment is done [19].

 

 

2.3 Environmental and Healthcare-Associated Stress

Antibiotic exposure is one of the most important stress factors bacteria face during the clinical infection period. While antibiotics aim to remove pathogens, sub-lethal or shifting drug amounts often occur inside patients from variability in drug movement, poor tissue penetration, or failing to adhere to the treatment. These situations do not instantly destroy bacteria but induce stress responses that sometimes make survival stronger [20]. Antibiotics directed at major cell processes like wall building, DNA copying, or making proteins can switch on global stress systems. Responses can consist of DNA repair mechanisms, metabolic changes, and growth stop, which overall reduce the antibiotic’s working ability [21]. Significantly, too, is when antibiotic-caused stress leads to more persister cell creation or tolerant traits, but does not push for permanent genetic resistance. In a clinical view, such survival through stress means longer infections and higher chances of the disease coming back after treatment is done [22].

3. Stress-Induced Phenotypic Adaptation Mechanisms

Exposure to different stresses in the clinical environment does not affect all bacteria in the population equally. Rather, stressful circumstances create phenotypic differences, so some bacteria can temporarily go into adaptive forms, increasing their chances for survival [23]. These adaptations caused by stress are reversible, do not involve changes in genes, and are tightly connected to persistence as well as antibiotic tolerance. Understanding these mechanisms explains why bacterial populations can live through antimicrobial treatment without classical resistance being gained [24].

3.1 Metabolic Downregulation and Growth Arrest

One ordinary adaptive reaction when bacteria are exposed to stress is that they reduce their metabolic rates. When facing low nutrients, pressure from the immune system, or when antibiotics are present, bacteria can reach slow-growing or even almost inactive states [25]. Most antibiotics act by killing bacteria by attacking processes that are actively happening in the cells, so less metabolic activity leads to a major reduction in the effectiveness of the antibiotics. Growth is arrested, which allows bacteria to save some energy and restrict how many antibiotic targets are produced, which adds to increased survival during treatments [26]. As a result, in clinics, this is the reason why sometimes antibiotics need to be given for a longer time or many times to clear the infection fully, and why bacteria can reappear after stopping treatments. Downregulation of metabolism can be reversed, so bacteria can start active growth again once stressful conditions are removed [27].

3.2 Activation of Global Stress Response Pathways

Bacteria have a conserved regulatory system that manages responding adaptively under stressful environmental situations. Among these, responses known as stringent and SOS are central in the adaptation of phenotype caused by stress. These global networks allow fast changes in gene expression when there is an adverse condition [28]. The stringent reaction becomes activated in the absence of nutrition and different stress triggers, causing a reduction in ribosome activity and changes for survival, including central metabolic shifts. This adaptation leads to stopping growth and increases tolerance against antibiotics, affecting protein synthesis and cell wall construction [29]. Likewise, the SOS system is triggered by damaged DNA, such as that from certain antibiotic usage. Despite its main role being to repair DNA, SOS activation also helps temporary survival through postponing cell division and modifying cellular functioning [30]. In clinical infectious scenarios, repeating these stress system activations leads to bacteria staying longer during antibiotic treatment, which improves the chances of not succeeding in therapy [31].

3.3 Biofilm-Associated Phenotypic Adaptation

Biofilm formation is a complicated response with adaptation to stress, which you often see inside chronic infections and in healthcare-related infections. Bacteria living in biofilms are covered by a self-made extracellular matrix that creates many different microenvironments around them [32]. Cells situated in the deeper layer of biofilm get less nutrients, lower oxygen amounts, and antibiotics below inhibitory levels, acting as signals of stress. These factors promote a variety of phenotypes, such as slow-growing cells and sleeping cells with increased tolerance for antimicrobial substances [33]. Stress adaptation related to biofilm strongly lowers the penetration and performance of antibiotics, causing infections to persist on medical devices and tissues of the host [34]. From a clinical perspective, adaptation of phenotype mediated by biofilm is a reason for numerous failed standard antimicrobial treatments in infections caused by devices or chronic ones, which often need surgery or removal of the device [35].

4. Microbial Persistence: Mechanisms and Clinical Significance

Microbial persistence is a unique mechanism of survival allowing some subset of bacterial cells to withstand exposure to deadly antibiotics when they do not possess inherited resistance mechanisms [36]. Different than resistant bacteria, persisters are genetically vulnerable to antibiotics but continue treatment through reversible physiology that permits them to repopulate after antimicrobial pressure is removed. More and more data are absolutely supportive of the claim that persistence as important factor in the failure and recurrence of infection, especially with chronic or repeated clinical infection forms [37].

4.1 Definition and Characteristics of Persister Cells

Persister cells are phenotypic variations among susceptible bacterial populations and show a temporary capacity for survival against improved antibiotic concentrations. Such cells generally display less metabolism, slower or stronger throwing, and less active engagement with antibiotic targets [38]. Notably, persistence is not passed down genetically; descendants of persister cells, once active growth resumes, regain antibiotic sensitivity [39]. In clinical situations, persister cells make infection treatment more difficult because usual antimicrobial testing cannot detect these types. So infections from groups holding persisters might appear microbiologically sensitive, but actually, they continue to be clinically resistant to therapy [40].

4.2 Mechanisms Underlying Persister Formation

Formation of persister cells is very much connected to stress-triggered changes in phenotype. Environmental pressure and antibiotic-caused stress can activate regulatory pathways that cause dormancy and keep the cell alive [41]. One commonly recognized method is the toxin-antitoxin system, which can block important cell functions, such as translation or DNA duplication, resulting in stopping growth. By decreasing metabolic performance, those systems lower the antibiotic action that requires active bacterial activity for killing [42]. On top of toxin-antitoxin control, general stress reactions like stringent response and SOS mechanisms help make persisters, through changing bacterial physiology to survival over growth [The bacterial population shows metabolic variety, which adds to the increasing possibility that some cells may move into a persister state if in a negative situation. These mechanisms are coordinated and also able to be reversed, helping bacteria survive in temporary stress during infection or medical treatment [44].

4.3 Clinical Evidence of Persistence in Chronic and Recurrent Infections

Persister cells are found in a wide variety of infections that hold clinical importance, usually with a longer-lasting time, relapse, and not a complete cure. For pulmonary infections, especially when it comes to opportunistic pathogens, groups of persistent cells lead to chronic persistence and repeated flare-ups even though patients receive antibiotics repeatedly [45]. Also, in infections that are related to inserted medical devices, persistent cells inside biofilm can act as a lasting reservoir, which may reseed infection after therapy using antimicrobials [46]. Tuberculosis is an important clinical example of persistence, in which long periods of multidrug therapy are needed to get rid of bacteria that grow slowly and remain dormant. This longer treatment length is due to trouble in removing persister cells, instead of regular resistance only [47]. Similar patterns may be found for chronic wounds and bone infection called osteomyelitis; the improvement of symptoms is mostly followed by a relapse after antibiotics have stopped [48].

4.4 Clinical Implications of Bacterial Persistence

Clinical effects of bacterial persistence are quite important in the long-term. Persistence leads to failure in treatment, a higher risk of relapse, longer therapies, and higher costs in the healthcare system [49]. Also, the persister population that survives can help to develop antimicrobial resistance further because they provide a safe area where genetic modifications have time to accumulate during the period. Even though these outcomes are present, persistence is not given enough attention in everyday clinical microbiology practice, which shows there is a need for better diagnostic knowledge and treatment approaches focused especially on persister traits [50].

5. Antibiotic Tolerance: A Distinct but Overlapping Survival Strategy

Antibiotic tolerance is another way for bacteria to survive that does not require them to develop real genetic resistance. Although it is regularly talked about with persistence, tolerance is different because bacteria are killed at a slower pace, instead of just a few managing to live fully. The knowledge of antibiotic tolerance has been rising, and makes people realize its big effect on long-term infections and bad responses to therapy in the clinic [51].

5.1 Conceptual Distinction Between Resistance, Tolerance, and Persistence

Antimicrobial resistance is known as the capability of bacteria to continue growing despite the antibiotics at levels meant to stop or destroy sensitive strains [52]. On the other hand, the concept of antibiotic tolerance is not about growth while in the presence of antibiotics, but rather means the bacteria can stay alive for long times after being exposed [53]. Persistence is a more intense version of tolerance; in this case, just a tiny part of the bacteria keeps living through very deep sleep phases with strong antibiotics [54].

To clarify these distinctions, a comparative framework is essential for clinical interpretation.5.2 Mechanisms Underlying Antibiotic Tolerance

Antibiotic tolerance occurs because of physiological modifications from stress that defend bacteria against killing by antibiotics [56]. Unlike persister formation, where only small groups of dormant bacteria exist, tolerance is caused by a population-wide move into physiological conditions that are less exposed to antibiotics. This includes less metabolic work, changes in cell envelope structures, and triggering stress response systems to minimize antibiotic-provoked damage [57]. Stress factors, such as limited nutrients, immune presence, and low antibiotic doses, can bring about tolerant types by causing a slower bacterial reproductive rate and lowering activity within antibiotic targets [58]. Since lots of antibiotics that kill bacteria need active cell walls, the effects reducing growth speed lead to less efficient killing. Such changes are not permanent, so bacteria recover their susceptibility when the conditions of the environment become better again [59].

5.3 Clinical Implications of Antibiotic Tolerance

The existence of antibiotic-tolerant bacterial groups has consequences for medical treatment measures. Tolerance can make bacterial clearance slower, leading to therapy needing to last longer, putting patients at increased risk from negative drug impacts. Some infections by tolerant bacterial types may look susceptible microbiologically but not respond correctly to treatment, so symptoms remain, or resolution is not complete [60]. Also, antibiotic tolerance acts as a forerunner of resistance growth by keeping bacteria alive in the presence of antimicrobial pressure longer. More exposure means a greater chance of resistant mutants arising, especially in chronic cases needing many more therapy sessions. Even with its serious clinical meaning, tolerance is not appreciated enough in normal microbiology routines, pointing out the necessity of improved knowledge and better diagnostic strategies [61].

6. Clinical Consequences: Treatment Failure and Recurrent Infections

Stress exposure by bacteria results in adaptation and persistence, as well as tolerance to antibiotics, bringing serious impacts on clinical results. Even though antimicrobial resistance is a main concern, strategies not based on genetic changes are now more and more commonly seen for the explanation of why infections do not resolve even in cases with seemingly suitable therapy. Such things lead to bacteria not being fully eliminated, relapse afterward, stopping treatment, and chronic infection formation in different clinical situations [62].

6.1 Treatment Failure Despite Apparent Antimicrobial Susceptibility

One of the most difficult outcomes of bacterial tolerance and persistence is when treatment fails, even if laboratory tests say antimicrobial drugs work in vitro. Regular susceptibility testing checks for blocking bacterial growth in ideal laboratory settings and does not involve stress-induced physiological states that bacteria may face inside patients. This means that infection can be caused from bacteria groups that look like they are susceptible, but with tolerant or persistent subgroups surviving the therapy [63]. In the clinic, this mismatch shows as slow or missing improvement of the patient, continued symptoms, and also a requirement for repeated antibiotics or longer treatment. Such results are often seen as low dosage or the patient not following instructions, but actually, they are coming from basic limits within current diagnostic approaches [64].

6.2 Role in Chronic Infections

Persistence and tolerance are important for how chronic bacterial infections develop. In these infections, bacteria deal with ongoing immune attacks and sometimes with antibiotic medicines [65]. For respiratory infections, bacteria adapt to a stressful environment and can continue living in the airways that have lots of mucus and not much oxygen, which encourages slow growth and less active metabolisms. These factors make the bacteria stay around longer and lead to sickness coming back many times [66].  In the same way, chronic wound infections feature biofilm-connected bacteria that are more tolerant and persistent, making topical and systemic antibiotics less effective. Not removing the bacteria leads to wounds taking longer to heal, a higher chance of problems, and needing more visits to healthcare providers [67].

6.3 Recurrent and Relapsing Infections

Recurrent infection usually occurs when persister cells stay alive after an antimicrobial medicine and then start to fill up the site of infection again after stopping treatment. This is more noticeable in cases with long-term therapy, and often people look like they are getting better when using the drug but see the infection return some weeks or months after finishing [68]. It happens often for infections that go deep in the body, like osteomyelitis, as well as endocarditis, where bacteria are meeting changing amounts of antibiotics and stress from the immune system [69]. When an infection comes back, not only does it make patients get sick, but it also makes doctors work harder because they must do more tests and give more antibiotics. In the end, this might help the resistant bacteria become more common, which means fewer medicines will work [70].

6.4 Impact on Healthcare Burden

Beyond only what happens for individual patients, treatment failure that is caused by persistence or tolerance also makes the healthcare system take on heavier loads. Hospital stays are longer, the use of antibiotics goes up, and doctors may need to perform more surgeries or take out the devices, all of which increase the cost of healthcare [71]. Also, broad-spectrum antibiotics being used again and again for the ongoing infections amplify antimicrobial pressure in whole populations, which speeds up the resistance spreading [72].

7. Diagnostic Challenges in Detecting Persistence and Tolerance

Despite having a remarkable role in that they fail treatments and infections return, bacterial persistence, as well as antibiotic tolerance,e remain unnoticed by the usual clinical microbiology process. The tests we use now are mostly made for finding a genetic resistance that lasts, not temporary types caused by stress. This missing diagnostic part is a big issue for infection control. It also lets survival approaches not related to resistance be underestimated [73].

7.1 Limitations of Conventional Antimicrobial Susceptibility Testing

Standard antimicrobial susceptibility tests rely on checking how much bacterial growth is reduced in laboratory situations. Usually, this uses a minimal inhibitory concentration number. This is good for finding resistant types, but it cannot always show phenotypic states if metabolism drops or killing by antibiotics changes. Cells known as tolerant or persisters are not growing when antibiotics are around, and so they look susceptible according to regular methods [74]. Additionally, susceptibility testing is done when there are a lot of nutrients with no stress, which is very different from the environment inside the host. The laboratory settings do not bring the same immune pressure limitations of nutrients or antibiotic concentration variations as infection in real life; this reduces how well test results predict for clinics. So, doctors may start or keep an antibiotic treatment based on laboratory data that does not show actual bacterial activity in vivo [75].

7.2 Absence of Routine Assays for Persistence and Tolerance

Specialized test procedures like time-kill studies or methods for persister quantification can be useful for finding tolerance and persistence, but these are not being used often in clinical laboratories because their processes are complicated, require more time, and do not have standardized interpretations. Such tests stay mainly inside research environments, and they are not commonly added for diagnostic decision purposes in clinics [76].

Missing standardized clinical definitions that are standardized and unclear diagnostic limit points make detection harder. Unlike resistance, which has established guidance and breakpoints that are accepted, persistence and tolerance do not have recognized diagnostic criteria that everyone agrees on. This lack of general agreement restricts their regular use within microbiology reports and for clinical management [77].

7.3 Diagnostic Challenges in Biofilm-Associated Infections

Biofilm-associated infections give extra problems for diagnosis because bacteria in biofilms have a mixed physiological status that is not well shown in planktonic cultures. Samples that are taken from infections related to biofilms might not exactly show the main stress-modified phenotypes that are actually happening inside the body. In this way, tests in the laboratory can understate how many bacteria live and overstate antibiotic action [78]. Apart from that, regular culturing methods often do not pick up slow-growing or sleepy cells, leading to false-negative findings or incomplete microbial evaluation. These restrictions are very critical with infections linked to medical devices and those that last in the long term, where bacteria inside biofilm are the main reason for staying and coming back [79].

7.4 Need for Improved Diagnostic Approaches

Failure to detect persistence and tolerance in standard diagnostic tests shows the need for new ways that mirror bacterial actions in medical situations. Strategies could involve tests of bacterial killing activity instead of simply growth suppression, markers reacting to stress, as well as diagnostic models that add host and environmental contributions. While these instruments are not broadly accessible, clinicians have to use clinical judgment and patient response to treatment, not just laboratory findings alone, in managing persistent or recurring infection [80].

8. Emerging Therapeutic Strategies to Target Persistence and Stress Adaptation

Understanding of bacterial adaptation to stress, persistence, and tolerance for antibiotics has drawn increased attention in treatments reaching beyond regular antimicrobial techniques. Since these ways of survival do not rely on stable genetic resistance, it needs new approaches that work to interrupt stress responses of bacteria, metabolic inactivity, and safe niches. New types of therapeutic strategies try to improve bacterial elimination, make treatment time shorter, and lower the chances for relapse in chronic infection [81].

8.1 Targeting Persister Cells

There are promising ways, including making agents that target persister cells and interrupt dormancy or cause metabolic activity. When persister cells are forced to resume growth, these methods can make bacteria more vulnerable to usual antibiotics [82]. Some compounds interfering with energy supply, inside the membrane, or with stress signal response have been shown to have the potential to sensitize sleeping cells to antimicrobial killing [83]. An alternative approach is to directly remove persister cells with agents that can kill bacteria not depending on growth conditions. Strategies aim to deal with limiting antibiotics since they need active cell processes, and so open new ways in the treatment of persistent infections [84].

8.2 Optimizing Combination and Sequential Therapy

Combination therapy is considered an established and still developing method for handling infection in tolerant bacteria or persistent groups. When antibiotics with complementary ways of functioning are used, doctors can improve bacterial elimination in different physiological conditions [85]. Sequential therapy, where antibiotics are given in a certain sequence to make use of shifts of bacterial stress response, has gained more focus as an approach to lowering survival with stress-adapted bacteria [86]. These approaches should be adjusted with great care, so we do not give unnecessary antimicrobials for longer durations and to minimize toxicity in patients. Their successful outcome is mostly related to greater knowledge of how bacteria adapt to stress, together with the timing of the treatment implementation [87].

8.3 Host-Directed and Adjunctive Therapies

Targeting host determinants that are responsible of bacteria stress adaptation shows another path for therapy. Host-directed therapies are designed to boost immune-based removal of bacteria, adjust the inflammation response, or change the infection microenvironment so that it prevents bacteria from surviving. If fewer selective pressures create persistence and tolerance, these tactics can work in addition to antimicrobial therapy and, by this, improve results in treatment [88]. There are also adjunctive therapies, like compounds disrupting biofilm or improving the antibiotic going inside, especially important for infections associated with devices and in chronic cases. These approaches deal with environmental factors that cause stress-adaptation, not by focusing directly on killing bacterial viability [89].

8.4 Implications for Clinical Practice

Adding strategies aimed at persistence and adaptation to stress into clinical routines requires a change in therapy perspectives. Instead of concentrating only on antimicrobial sensitivity, choices in treatment ought to consider both bacterial physiological conditions and dynamic infection surroundings. Many methods are still undergoing research, but including them with clinical guidance can be promising to improve results for infections, which are usually linked with increased rates of failed treatment or recurring infection [90].

9. Future Perspectives and Research Directions

To move clinical management of chronic and recurring bacterial infection, it is often needed for a major change beyond only looking at antimicrobial resistance. Upcoming research must focus more on new diagnostic techniques that can discover stress-caused bacterial conditions, such as persistence and tolerance, in situations that better reflect the infection in the living body. Mixing up how bacteria get killed, markers of metabolic activities, as well as host stress signs inside diagnostic models, may give better predictions for treatment results [91].

Therapy progress should pay attention to plans that break up stress reactions of bacteria and remove sleeping or slow-growing types. This will include discovering anti-persister substances, making combination therapy and sequential treatment effective, and using host-focused options to change infection environments [92]. Translational studies that connect lab results with clinical records are necessary for validating these directions and to guide rules that use evidence in treatment [93]. To sum up, putting improved knowledge regarding persistence and tolerance in programs for antimicrobial policy can assist in cutting unnecessary antibiotic usage, lowering the chance of relapse, and stopping the development of resistance. An approach that covers microbiological, clinical, and host influences is absolutely important for facing an ongoing problem in failed treatment among some bacterial infections [94].

10. Conclusion

Failure of treatment and recurring bacterial infections still pose many problems in medical practices, even when antimicrobial resistance cannot be identified. This article discusses stress-caused bacterial adaptations, persistence, and antibiotic tolerance as important yet not usually addressed factors in these situations. These non-genetic bacterial types can allow temporary survival in aggressive conditions involving the host, antibiotics, and healthcare environments. They cause challenges for antimicrobial therapies and create more problems in infection management. Persistence and tolerance are challenging, as normal use of antimicrobial sensitivity testing shows a gap between lab susceptibility and actual treatment reactions in the patient. The feature of being reversible and unequal lets bacterial groups escape removal, promotes relapse, and could help the rise of resistance during continued or repeated therapy. To recognize these methods is important for more accurate clinical failure interpretation and helpful in therapeutic choices. To deal with the survival of bacteria caused by stress, there is a need for improvements in diagnostic tools, therapies that target populations that are dormant or tolerant, and to move these ideas into greater clinical microbiology and stewardship by antimicrobial frameworks. Deeper insights into physiological adaptation in bacteria inside clinical settings provide an important chance to improve the outcome of treatment,  reduce recurring cases, and cut the long-term effects of bacterial infections difficult to treat.

Ethical Considerations

This review article was prepared following principles of academic integrity and responsible scholarship. All information included in the manuscript was obtained from published scientific literature and appropriately cited. Grammarly was used solely as a writing assistance tool to improve grammar, spelling, punctuation, and language clarity. The selection, evaluation, interpretation, and synthesis of the reviewed literature were conducted entirely by the authors. Grammarly did not contribute to the scientific content, critical analysis, conclusions, or intellectual contributions presented in this review. All final decisions regarding the manuscript content remained the responsibility of the authors.

Reference:

1. Mo, Y., Tan, W. C., & Cooper, B. S. [2025]. Antibiotic duration for common bacterial infections: a systematic review. JAC-antimicrobial resistance, 7[1], dlae215. https://doi.org/10.1093/jacamr/dlae215
2. Nazir, A., Nazir, A., Zuhair, V., Aman, S., Sadiq, S. U. R., Hasan, A. H., Tariq, M., Rehman, L. U., Mustapha, M. J., & Bulimbe, D. B. [2025]. The Global Challenge of Antimicrobial Resistance: Mechanisms, Case Studies, and Mitigation Approaches. HealScience Reportsrts, 8[7], e71077. https://doi.org/10.1002/hsr2.71077
3. Dawan, J., & Ahn, J. [2022]. Bacterial Stress Responses as Potential Targets in Overcoming Antibiotic Resistance. Microorganisms, 10[7], 1385. https://doi.org/10.3390/microorganisms10071385
4. Foster P. L. [2007]. Stress-induced mutagenesis in bacteria. Critical reviews in biochemistry and molecular biology, 42[5], 373–397. https://doi.org/10.1080/10409230701648494
5. Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. [2020]. Antibiotic resistance and persistence-Implications for human health and treatment perspectives. EMBO reports, 21[12], e51034. https://doi.org/10.15252/embr.202051034
6. Wood, T. K., Knabel, S. J., & Kwan, B. W. [2013]. Bacterial persister cell formation and dormancy. Applied and Environmental Microbiology, 79[23], 7116–7121. https://doi.org/10.1128/AEM.02636-13
7. Westblade, L. F., Errington, J., & Dörr, T. [2020]. Antibiotic tolerance. PLoS pathogens, 16[10], e1008892. https://doi.org/10.1371/journal.ppat.1008892
8. Windels, E. M., Michiels, J. E., Van den Bergh, B., Fauvart, M., & Michiels, J. [2019]. Antibiotics: Combatting Tolerance To Stop Resistance. mBio, 10[5], e02095-19. https://doi.org/10.1128/mBio.02095-19
9. Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. [2023]. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare [Basel, Switzerland], 11[13], 1946. https://doi.org/10.3390/healthcare11131946
10. Niu, H., Gu, J., & Zhang, Y. [2024]. Bacterial persisters: molecular mechanisms and therapeutic development. Signal transduction and targeted therapy, 9[1], 174. https://doi.org/10.1038/s41392-024-01866-5
11. Hakansson, A. P., Orihuela, C. J., & Bogaert, D. [2018]. Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection. Physiological Reviews 98[2], 781–811. https://doi.org/10.1152/physrev.00040.2016
12. Brand, C., Newton-Foot, M., Grobbelaar, M., & Whitelaw, A. [2025]. Antibiotic-induced stress responses in Gram-negative bacteria and their role in antibiotic resistance. The Journal of Antimicrobial Chemotherapy, 80[5], 1165–1184. https://doi.org/10.1093/jac/dkaf068
13. Flannagan, R. S., Heit, B., & Heinrichs, D. E. [2015]. Antimicrobial Mechanisms of Macrophages and the Immune Evasion Strategies of Staphylococcus aureus. Pathogens [Basel, Switzerland], 4[4], 826–868. https://doi.org/10.3390/pathogens4040826
14. Chautrand, T., Souak, D., Chevalier, S., & Duclairoir-Poc, C. [2022]. Gram-Negative Bacterial Envelope Homeostasis under Oxidative and Nitrosative Stress. Microorganisms, 10[5], 924. https://doi.org/10.3390/microorganisms10050924
15. Amarnath, K., Narla, A. V., Pontrelli, S., Dong, J., Reddan, J., Taylor, B. R., Caglar, T., Schwartzman, J., Sauer, U., Cordero, O. X., & Hwa, T. [2023]. Stress-induced metabolic exchanges between complementary bacterial types underly a dynamic mechanism of inter-species stress resistance. Nature communications, 14[1], 3165. https://doi.org/10.1038/s41467-023-38913-8
16. Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. [2023]. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. Chemical Reviews, 123[1], 31–72. https://doi.org/10.1021/acs.chemrev.2c00431
17. Elbaiomy, R. G., El-Sappah, A. H., Guo, R., Luo, X., Deng, S., Du, M., Jian, X., Bakeer, M., Li, Z., & Zhang, Z. [2025]. Antibiotic Resistance: A Genetic and Physiological Perspective. MedComm, 6[11], e70447. https://doi.org/10.1002/mco2.70447
18. Kohanski, M. A., Dwyer, D. J., & Collins, J. J. [2010]. How antibiotics kill bacteria: from targets to networks. Nature Reviews. Microbiology, 8[6], 423–435. https://doi.org/10.1038/nrmicro2333
19. Kunnath, A. P., Suodha Suoodh, M., Chellappan, D. K., Chellian, J., & Palaniveloo, K. [2024]. Bacterial Persister Cells and Development of Antibiotic Resistance in Chronic Infections: An Update. British journal of biomedical science, 81, 12958. https://doi.org/10.3389/bjbs.2024.12958
20. Nolan, C., & Behrends, V. [2021]. Sub-Inhibitory Antibiotic Exposure and Virulence in Pseudomonas aeruginosa. Antibiotics, 10[11], 1393. https://doi.org/10.3390/antibiotics10111393
21. Baran, A., Kwiatkowska, A., & Potocki, L. [2023]. Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race. International Journal of Molecular Sciences, 24[6], 5777. https://doi.org/10.3390/ijms24065777
22. Yuan, S., Shen, Y., Quan, Y., Gao, S., Zuo, J., Jin, W., Li, R., Yi, L., Wang, Y., & Wang, Y. [2024]. Molecular mechanism and application of emerging technologies in the study of bacterial persisters. BMC microbiology, 24[1], 480. https://doi.org/10.1186/s12866-024-03628-3
23. Rapacka-Zdonczyk A. [2026]. Beyond Resistance: Phenotypic Plasticity in Bacterial Responses to Antibiotics, Oxidative Stress and Antimicrobial Photodynamic Inactivation. Molecules [Basel, Switzerland], 31[3], 567. https://doi.org/10.3390/molecules31030567
24. Trastoy, R., Manso, T., Fernández-García, L., Blasco, L., Ambroa, A., Pérez Del Molino, M. L., Bou, G., García-Contreras, R., Wood, T. K., & Tomás, M. [2018]. Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments. ClinicaMicrobiology Reviewsws, 31[4], e00023-18. https://doi.org/10.1128/CMR.00023-18
25. Cabral, D. J., Wurster, J. I., & Belenky, P. [2018]. Antibiotic Persistence as a Metabolic Adaptation: Stress, Metabolism, the Host, and New Directions. Pharmaceuticals [Basel, Switzerland], 11[1], 14. https://doi.org/10.3390/ph11010014
26. Stokes, J. M., Lopatkin, A. J., Lobritz, M. A., & Collins, J. J. [2019]. Bacterial Metabolism and Antibiotic Efficacy. CelMetabolisms, 30[2], 251–259. https://doi.org/10.1016/j.cmet.2019.06.009
27. Gjini, E., Paupério, F. F. S., & Ganusov, V. V. [2020]. Treatment timing shifts the benefits of short and long antibiotic treatment over infection. Evolution, medicine, and public health, 2020[1], 249–263. https://doi.org/10.1093/emph/eoaa033
28. Boutte, C. C., & Crosson, S. [2013]. Bacterial lifestyle shapes stringent response activation. Trends in Microbiology 21[4], 174–180. https://doi.org/10.1016/j.tim.2013.01.002
29. Zhu, M., & Dai, X. [2023]. Stringent response ensures the timely adaptation of bacterial growth to nutrient downshift. Nature communications, 14[1], 467. https://doi.org/10.1038/s41467-023-36254-0
30. Ghosh, S., & Orman, M. A. [2024]. Exploring the links between SOS response, mutagenesis, and resistance during the recovery period. Antimicrobial Agents and Chemotherapy, 68[5], e0146223. https://doi.org/10.1128/aac.01462-23
31. Lee, S., Hinz, A., Bauerle, E., Angermeyer, A., Juhaszova, K., Kaneko, Y., Singh, P. K., & Manoil, C. [2009]. Targeting a bacterial stress response to enhance antibiotic action. Proceedings of the National Academy of Sciences of the United States of America, 106[34], 14570–14575. https://doi.org/10.1073/pnas.0903619106
32. Sharma, S., Mohler, J., Mahajan, S. D., Schwartz, S. A., Bruggemann, L., & Aalinkeel, R. [2023]. Microbial Biofilm: A Review on Formation, Infection, Antibiotic Resistance, Control Measures, and Innovative Treatment. Microorganisms, 11[6], 1614. https://doi.org/10.3390/microorganisms11061614
33. Uruén, C., Chopo-Escuin, G., Tommassen, J., Mainar-Jaime, R. C., & Arenas, J. [2020]. Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics [Basel, Switzerland], 10[1], 3. https://doi.org/10.3390/antibiotics10010003
34. Almatroudi A. [2025]. Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts. Biology, 14[2], 165. https://doi.org/10.3390/biology14020165
35. Domouchtsidou, A., Ioannou, P., Lianou, A., Tsante, K. A., Tsakri, D., Bonova, E., Baliou, S., Fortis, S. P., Chaldoupis, A. E., Samonis, G., Koutserimpas, C., Sokou, R., Papadopoulos, D. V., & Tsantes, A. G. [2026]. Biofilms in clinical infection: pathophysiology, diagnosis, and the evolving therapeutic landscape. Journal ofClinical Microbiologyy, 64[3], e0104225. https://doi.org/10.1128/jcm.01042-25
36. Cabral, D. J., Wurster, J. I., & Belenky, P. [2018]. Antibiotic Persistence as a Metabolic Adaptation: Stress, Metabolism, the Host, and New Directions. Pharmaceuticals [Basel, Switzerland], 11[1], 14. https://doi.org/10.3390/ph11010014
37. Nath, A., & Rodríguez-Rojas, A. [2026]. Persistent Gaps in the Ultimate Mechanisms of Antimicrobial-Induced Bacterial Killing. Antibiotics, 15[3], 244. https://doi.org/10.3390/antibiotics15030244
38. Kim, T.-J. [2026]. Bacterial Persister Cells as Evolutionary Catalysts of Antibiotic Resistance: Mechanisms, Clinical Implications, and Therapeutic Strategies. Antibiotics, 15[6], 526. https://doi.org/10.3390/antibiotics15060526
39. Wood, T. K., Knabel, S. J., & Kwan, B. W. [2013]. Bacterial persister cell formation and dormancy. Applied and Environmental Microbiology, 79[23], 7116–7121. https://doi.org/10.1128/AEM.02636-13
40. Bartell, J. A., Cameron, D. R., Mojsoska, B., Haagensen, J. A. J., Pressler, T., Sommer, L. M., Lewis, K., Molin, S., & Johansen, H. K. [2020]. Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment. PLoS pathogens, 16[12], e1009112. https://doi.org/10.1371/journal.ppat.1009112
41. Berkvens, A., Chauhan, P., & Bruggeman, F. J. [2022]. Integrative biology of persister cell formation: molecular circuitry, phenotypic diversification and fitness effects. Journal of the Royal Society, Interface, 19[194], 20220129. https://doi.org/10.1098/rsif.2022.0129
42. Yang, Q. E., & Walsh, T. R. [2017]. Toxin-antitoxin systems and their role in disseminating and maintaining antimicrobial resistance. FEMMicrobiology Reviews, 41[3], 343–353. https://doi.org/10.1093/femsre/fux006
43. Sonika, S., Singh, S., Mishra, S., & Verma, S. [2023]. Toxin-antitoxin systems in bacterial pathogenesis. Heliyon, 9[4], e14220. https://doi.org/10.1016/j.heliyon.2023.e14220
44. Eisenreich, W., Rudel, T., Heesemann, J., & Goebel, W. [2021]. Persistence of Intracellular Bacterial Pathogens-With a Focus on the Metabolic Perspective. Frontiers in cellular and infection microbiology, 10, 615450. https://doi.org/10.3389/fcimb.2020.615450
45. Lewis K. [2012]. Persister cells: molecular mechanisms related to antibiotic tolerance. Handbook of experimental pharmacology, [211], 121–133. https://doi.org/10.1007/978-3-642-28951-4_8
46. Mishra, A., Aggarwal, A., & Khan, F. [2024]. Medical Device-Associated Infections Caused by Biofilm-Forming Microbial Pathogens and Controlling Strategies. Antibiotics [Basel, Switzerland], 13[7], 623. https://doi.org/10.3390/antibiotics13070623
47. Connolly, L. E., Edelstein, P. H., & Ramakrishnan, L. [2007]. Why is long-term therapy required to cure tuberculosis?. PLoS medicine, 4[3], e120. https://doi.org/10.1371/journal.pmed.0040120
48. Panteli, M., & Giannoudis, P. V. [2017]. Chronic osteomyelitis: what the surgeon needs to know. EFORT open reviews, 1[5], 128–135. https://doi.org/10.1302/2058-5241.1.000017
49. La Rosa, R., Johansen, H. K., & Molin, S. [2022]. Persistent Bacterial Infections, Antibiotic Treatment Failure, and Microbial Adaptive Evolution. Antibiotics [Basel, Switzerland], 11[3], 419. https://doi.org/10.3390/antibiotics11030419
50. Hossain, T., Deter, H. S., Peters, E. J., & Butzin, N. C. [2021]. Antibiotic tolerance, persistence, and resistance of the evolved minimal cell, Mycoplasma mycoides JCVI-Syn3B. iScience, 24[5], 102391. https://doi.org/10.1016/j.isci.2021.102391
51. Michaux, C., Ronneau, S., Giorgio, R. T., & Helaine, S. [2022]. Antibiotic tolerance and persistence have distinct fitness trade-offs. PLoS pathogens, 18[11], e1010963. https://doi.org/10.1371/journal.ppat.1010963
52. Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. [2023]. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare [Basel, Switzerland], 11[13], 1946. https://doi.org/10.3390/healthcare11131946
53. Dörr T. [2021]. Understanding tolerance to cell wall-active antibiotics. Annals of the New York Academy of Sciences, 1496[1], 35–58. https://doi.org/10.1111/nyas.14541
54. Pan, X., Liu, W., Du, Q., Zhang, H., & Han, D. [2023]. Recent Advances in Bacterial Persistence Mechanisms. International Journal of Molecular Sciences, 24[18], 14311. https://doi.org/10.3390/ijms241814311
55. Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. [2016]. Distinguishing between resistance, tolerance,e and persistence to antibiotic treatment. Nature Reviews Microbiology. Microbiology, 14[5], 320–330. https://doi.org/10.1038/nrmicro.2016.34
56. Liu, Y., Yang, K., Zhang, H., Jia, Y., & Wang, Z. [2020]. Combating Antibiotic Tolerance Through Activating Bacterial Metabolism. Frontiers in Microbiology, 11, 577564. https://doi.org/10.3389/fmicb.2020.577564
57. Orman, M. A., Ngo, H. G., & Mohiuddin, S. G. [2026]. Beyond metabolic dormancy: metabolic rewiring in bacterial persistence. Nature communications, 17[1], 3536. https://doi.org/10.1038/s41467-026-71427-7
58. Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. [2023]. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Pharmaceuticals, 16[11], 1615. https://doi.org/10.3390/ph16111615
59. Cylke, C., Si, F., & Banerjee, S. [2022]. Effects of antibiotics on bacterial cell morphology and their physiological origins. Biochemical Society transactions, 50[5], 1269–1279. https://doi.org/10.1042/BST20210894
60. Chinemerem Nwobodo, D., Ugwu, M. C., Oliseloke Anie, C., Al-Ouqaili, M. T. S., Chinedu Ikem, J., Victor Chigozie, U., & Saki, M. [2022]. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Journal of Clinical Laboratory Analysis, 36[9], e24655. https://doi.org/10.1002/jcla.24655
61. Windels, E. M., Michiels, J. E., Fauvart, M., Wenseleers, T., Van den Bergh, B., & Michiels, J. [2019]. Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates. The ISME Journal, 13[5], 1239–1251. https://doi.org/10.1038/s41396-019-0344-9
62. Santi, I., Manfredi, P., Maffei, E., Egli, A., & Jenal, U. [2021]. Evolution of Antibiotic Tolerance Shapes Resistance Development in Chronic Pseudomonas aeruginosa Infections. mBio, 12[1], e03482-20. https://doi.org/10.1128/mBio.03482-20
63. Lewis, K., Lee, R. E., Brötz-Oesterhelt, H., Hiller, S., Rodnina, M. V., Schneider, T., Weingarth, M., & Wohlgemuth, I. [2024]. Sophisticated natural products as antibiotics. Nature, 632[8023], 39–49. https://doi.org/10.1038/s41586-024-07530-w
64. Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., Gould, I. M., Ramsay, C. R., & Michie, S. [2017]. Interventions to improve antibiotic prescribing practices for hospital inpatients. The Cochrane database of systematic reviews, 2[2], CD003543. https://doi.org/10.1002/14651858.CD003543.pub4
65. Grant, S. S., & Hung, D. T. [2013]. Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence, 4[4], 273–283. https://doi.org/10.4161/viru.23987
66. Jiang, X., & Zhang, S. [2025]. Respiratory microbiota, host immunity, respiratory viral infections and malignant tumors. Frontiers in Microbiology, 16, 1626077. https://doi.org/10.3389/fmicb.2025.1626077
67. Sen, C. K., Roy, S., Mathew-Steiner, S. S., & Gordillo, G. M. [2021]. Biofilm Management in Wound Care. Plastic and Reconstructive Surgery, 148[2], 275e–288e. https://doi.org/10.1097/PRS.0000000000008142
68. Madhusoodanan J. [2022]. How persister bacteria evade antibiotics, prolong infections. Proceedings of the National Academy of Sciences of the United States of America, 119[41], e2215617119. https://doi.org/10.1073/pnas.2215617119
69. Ciampolini, J., & Harding, K. G. [2000]. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?. Postgraduate Medical Journal, 76[898], 479–483. https://doi.org/10.1136/pmj.76.898.479
70. Sole, E., Trinchera, M., De Gaetano, S., Midiri, A., Piccolo, G., Mancuso, G., Schepici, G., & Biondo, C. [2025]. The Paradox of Healthcare in the ‘Superbugs’ Era: Current Challenges and Future Directions. Pathogens, 14[12], 1199. https://doi.org/10.3390/pathogens14121199
71. Poudel, A. N., Zhu, S., Cooper, N., Little, P., Tarrant, C., Hickman, M., & Yao, G. [2023]. The economic burden of antibiotic resistance: A systematic review and meta-analysis. PloS one, 18[5], e0285170. https://doi.org/10.1371/journal.pone.0285170
72. Llor, C., & Bjerrum, L. [2014]. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Therapeutic advances in drug safety, 5[6], 229–241. https://doi.org/10.1177/2042098614554919
73. Amábile-Cuevas, C. F., & Lund-Zaina, S. [2024]. Non-Canonical Aspects of Antibiotics and Antibiotic Resistance. Antibiotics, 13[6], 565. https://doi.org/10.3390/antibiotics13060565
74. Kadeřábková, N., Mahmood, A. J. S., & Mavridou, D. A. I. [2024]. Antibiotic susceptibility testing using minimum inhibitory concentration [MIC] assays. npj antimicrobials and resistance, 2[1], 37. https://doi.org/10.1038/s44259-024-00051-6
75. Munita, J. M., & Arias, C. A. [2016]. Mechanisms of Antibiotic Resistance. Microbiology Spectrum, 4[2], 10.1128/microbiolspec.VMBF-0016-2015. https://doi.org/10.1128/microbiolspec.VMBF-0016-2015
76. Alexandersen, N. R., Nielsen, K. L., Häussler, S., Bjarnsholt, T., & Schønning, K. [2025]. Antibiotic tolerance and persistence in clinical isolates of Escherichia coli evaluated by high-resolution time-kill assays. Microbiology spectrum, 13[9], e0112425. https://doi.org/10.1128/spectrum.01124-25
77. Yamin, D., Uskoković, V., Wakil, A. M., Goni, M. D., Shamsuddin, S. H., Mustafa, F. H., Alfouzan, W. A., Alissa, M., Alshengeti, A., Almaghrabi, R. H., Fares, M. A. A., Garout, M., Al Kaabi, N. A., Alshehri, A. A., Ali, H. M., Rabaan, A. A., Aldubisi, F. A., Yean, C. Y., & Yusof, N. Y. [2023]. Current and Future Technologies for the Detection of Antibiotic-Resistant Bacteria. Diagnostics [Basel, Switzerland], 13[20], 3246. https://doi.org/10.3390/diagnostics13203246
78. Lebeaux, D., Ghigo, J. M., & Beloin, C. [2014]. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiology and molecular biology review: MMBR, 78[3], 510–543. https://doi.org/10.1128/MMBR.00013-14
79. Hu, J. C., & Sethi, S. [2024]. New methods to detect bacterial or viral infections in patients with chronic obstructive pulmonary disease. Expert review of respiratory medicine, 18[9], 693–707. https://doi.org/10.1080/17476348.2024.2396413
80. Alidriss, O. M., AlSudais, H., Alhumaidan, O. S., Altwaijry, H. D., Bakhsh, A., Almuhanna, Y., Alkudmani, Z. S., Alqarni, I. A., Alenazi, D., Aljasham, A. T., & Jamous, Y. F. [2025]. Targeted Drug Delivery Strategies in Overcoming Antimicrobial Resistance: Advances and Future Directions. Pharmaceutics, 17[11], 1426. https://doi.org/10.3390/pharmaceutics17111426
81. Windels, E. M., Van den Bergh, B., & Michiels, J. [2020]. Bacteria under antibiotic attack: Different strategies for evolutionary adaptation. PLoS pathogens, 16[5], e1008431. https://doi.org/10.1371/journal.ppat.1008431
82. Hashemi, M. J., Dhaouadi Khattab, Y., & Ren, D. [2025]. Mini review: Persister cell control strategies. Frontiers in Pharmacology, 16, 1706115. https://doi.org/10.3389/fphar.2025.1706115
83. Schrank, C. L., Wilt, I. K., Monteagudo Ortiz, C., Haney, B. A., & Wuest, W. M. [2021]. Using membrane-perturbing small molecules to target chronic persistent infections. RSCMedicinal Chemistryy, 12[8], 1312–1324. https://doi.org/10.1039/d1md00151e
84. Stojowska-Swędrzyńska, K., Kuczyńska-Wiśnik, D., & Laskowska, E. [2023]. New Strategies to Kill Metabolically-Dormant Cells Directly Bypassing the Need for Active Cellular Processes. Antibiotics [Basel, Switzerland], 12[6], 1044. https://doi.org/10.3390/antibiotics12061044
85. Tängdén T. [2014]. Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Upsala journal of medical sciences, 119[2], 149–153. https://doi.org/10.3109/03009734.2014.899279
86. Kratz, J. C., & Banerjee, S. [2024]. Gene expression tradeoffs determine bacterial survival and adaptation to antibiotic stress. biRxiv: the preprint server for biology, 2024.01.20.576495. https://doi.org/10.1101/2024.01.20.576495
87. Serapide, F., Rotundo, S., Gallelli, L., Palleria, C., Colosimo, M., Gullì, S. P., Marcianò, G., & Russo, A. [2025]. The Changing Landscape of Antibiotic Treatment: Reevaluating Treatment Length in the Age of New Agents. Antibiotics [Basel, Switzerland], 14[7], 727. https://doi.org/10.3390/antibiotics14070727
88. Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. [2018]. Host-directed therapies for bacterial and viral infections. Nature Reviews. Drug Discovery, 17[1], 35–56. https://doi.org/10.1038/nrd.2017.162
89. Mirghani, R., Saba, T., Khaliq, H., Mitchell, J., Do, L., Chambi, L., Diaz, K., Kennedy, T., Alkassab, K., Huynh, T., Elmi, M., Martinez, J., Sawan, S., & Rijal, G. [2022]. Biofilms: Formation, drug resistance and alternatives to conventional approaches. Microbiology, 8[3], 239–277. https://doi.org/10.3934/microbiol.2022019
90. Murugaiyan, J., Kumar, P. A., Rao, G. S., Iskandar, K., Hawser, S., Hays, J. P., Mohsen, Y., Adukkadukkam, S., Awuah, W. A., Jose, R. A. M., Sylvia, N., Nansubuga, E. P., Tilocca, B., Roncada, P., Roson-Calero, N., Moreno-Morales, J., Amin, R., Kumar, B. K., Kumar, A., … van Dongen, M. B. M., on behalf of the Global AMR Insights Ambassador Network. [2022]. Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics. Antibiotics, 11[2], 200. https://doi.org/10.3390/antibiotics11020200
91. Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. [2024]. An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms, 12[9], 1920. https://doi.org/10.3390/microorganisms12091920
92. Serrano, S., Grujović, M. Ž., Marković, K. G., Barreto-Crespo, M. T., & Semedo-Lemsaddek, T. [2025]. From Dormancy to Eradication: Strategies for Controlling Bacterial Persisters in Food Settings. Foods, 14[6], 1075. https://doi.org/10.3390/foods14061075
93. Wichman, C., Smith, L. M., & Yu, F. [2020]. A framework for clinical and translational research in the era of rigor and reproducibility. Journal of Clinical and Translational Science 5[1], e31. https://doi.org/10.1017/cts.2020.523
94. Khadse, S. N., Ugemuge, S., & Singh, C. [2023]. Impact of Antimicrobial Stewardship on Reducing Antimicrobial Resistance. Cureus, 15[12], e49935. https://doi.org/10.7759/cureus.49935